Why do I have bleeding episodes twice a month while using the Nexplanon (etonogestrel) implant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Bleeding Twice Monthly on Nexplanon: Understanding and Management

Bleeding episodes twice a month while using Nexplanon is a common and expected side effect of the etonogestrel implant, occurring in approximately 7% of users who experience frequent bleeding patterns, and this is generally not harmful. 1

Why This Happens

The etonogestrel implant fundamentally alters your normal menstrual bleeding pattern. According to pooled data from 11 clinical trials:

  • 22% experience amenorrhea (no bleeding)
  • 34% have infrequent spotting
  • 7% report frequent bleeding (your situation)
  • 18% experience prolonged bleeding 1

Your bleeding pattern in the first 3 months broadly predicts future patterns 2. If you're experiencing frequent bleeding early on, there's approximately a 50% chance this pattern will improve over time, though it may persist 2.

What You Should Do First

Rule out underlying problems if clinically indicated 1:

  • Pregnancy - Consider testing if your pattern changes abruptly
  • STDs (chlamydia/gonorrhea) - Unscheduled bleeding can signal infection
  • Medication interactions - Certain drugs reduce Nexplanon effectiveness
  • New uterine pathology - Polyps or fibroids

Treatment Options If Bleeding Bothers You

If no underlying problem is found and you want treatment 1:

First-Line Treatment

  • NSAIDs for 5-7 days during bleeding episodes (mefenamic acid 500mg three times daily or celecoxib 200mg daily have shown effectiveness) 1

Second-Line Treatment (if medically eligible)

  • Low-dose combined oral contraceptives for 10-20 days during bleeding 1
  • Estrogen alone for 10-20 days during bleeding 1

Important caveat: Recent evidence shows that norethisterone (a progestogen) can stop bleeding episodes but does not prevent recurrence - bleeding typically returns within 5-10 days 3. Tranexamic acid showed no benefit in a 2026 randomized trial 4.

When to Consider Removal

If irregular bleeding persists and you find it unacceptable despite treatment, switching to an alternative contraceptive method is appropriate 1. In clinical trials, 11-13% of users discontinued specifically due to bleeding irregularities 2, 5.

Key Counseling Points

  • This bleeding is not harmful - it doesn't indicate damage or health risk 1, 6
  • Heavier women may experience more bleeding than lighter women 7
  • Prior irregular menses increases your risk of bothersome bleeding with the implant 8
  • Previous use of progestin injection or implant actually reduces odds of bleeding problems 8
  • Higher etonogestrel levels correlate with more bleeding - this is individual pharmacologic variation 9

The Bottom Line

Your twice-monthly bleeding represents frequent bleeding, affecting roughly 1 in 14 Nexplanon users. While treatment with NSAIDs or short-term hormonal therapy can help manage episodes, the bleeding pattern you experience in months 1-3 is your best predictor of long-term patterns 10, 2. If this pattern is unacceptable to you, transitioning to an alternative contraceptive method is a reasonable choice rather than continuing to manage recurrent bleeding episodes.

References

Research

The effects of Implanon on menstrual bleeding patterns.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2008

Guideline

contraception for adolescents.

Pediatrics, 2014

Research

Contraceptive Implant-Associated Bleeding in Adolescent/Young Adult Clinical Practice: Associated Factors, Management, and Rates of Discontinuation.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.